Atorvastatin calcium trihydrate

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Chemical-gene interaction
• Descriptors
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
PMID:29574565	IVTH	0.00001 M	0.00001 M	Decreased testosterone levels	Reproductive endocrine-mediated perturbations
	IVTH	0.00001 M	0.00001 M	Decreased progesterone levels	Reproductive endocrine-mediated perturbations
	IVTH	0.00001 M	0.00001 M	Decreased 17-OH-progesterone levels	Reproductive endocrine-mediated perturbations
	IVR	32 mg/kg/day	32 mg/kg/day	Affects steroid metabolism	Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
	IVTH	0.00001 M	0.00001 M	Decreased 17-OH-pregnenolone levels	Reproductive endocrine-mediated perturbations
	IVR	32 mg/kg/day	32 mg/kg/day	Decrease in corticosterone levels	Neurological endocrine-mediated perturbations
	IVTH	0.00001 M	0.00001 M	Decreased androstenedione levels	Reproductive endocrine-mediated perturbations
	IVR	32 mg/kg/day	32 mg/kg/day	Affects steroidogenesis	Reproductive endocrine-mediated perturbations
	IVTH	0.00001 M	0.00001 M	Decreased pregnenolone levels	Reproductive endocrine-mediated perturbations
	IVR	32 mg/kg/day	32 mg/kg/day	Decreased testosterone levels	Reproductive endocrine-mediated perturbations
	IVTH	0.00001 M	0.00001 M	Decrease in cortisol levels	Neurological endocrine-mediated perturbations
	IVR	32 mg/kg/day	32 mg/kg/day	Decreased androstenedione levels	Reproductive endocrine-mediated perturbations
	IVTH	0.00001 M	0.00001 M	Affects steroid metabolism	Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
	IVR	32 mg/kg/day	32 mg/kg/day	Decreased progesterone levels	Reproductive endocrine-mediated perturbations
	IVTH	0.00001 M	0.00001 M	Decreased Dehydroepiandrosterone (DHEA) levels	Metabolic endocrine-mediated perturbations
	IVR	32 mg/kg/day	32 mg/kg/day	Decreased 17-OH-progesterone levels	Reproductive endocrine-mediated perturbations
	IVR	32 mg/kg/day	32 mg/kg/day	Decreased 17-OH-pregnenolone levels	Reproductive endocrine-mediated perturbations
	IVR	32 mg/kg/day	32 mg/kg/day	Decreased pregnenolone levels	Reproductive endocrine-mediated perturbations
	IVTH	0.00000001 M	0.00000001 M	Affects steroid metabolism	Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations
	IVTH	0.0000001 M	0.0000001 M	Decreased Dehydroepiandrosterone (DHEA) levels	Metabolic endocrine-medi
	IVTH	0.0000001 M	0.0000001 M	Decreased testosterone levels
	IVTH	0.0000001 M	0.0000001 M	Affects steroid metabolism
	IVTH	0.0000001 M	0.0000001 M	Decreased progesterone levels
	IVTH	0.0000001 M	0.0000001 M	Decreased 17-OH-pregnenolone levels
	IVTH	0.0000001 M	0.0000001 M	Decrease in cortisol levels
	IVTH	0.0000001 M	0.0000001 M	Decreased androstenedione levels
	IVTH	0.0000001 M	0.0000001 M	Decreased pregnenolone levels
	IVTH	0.0000001 M	0.0000001 M	Decreased 17-OH-progesterone levels
	IVR	2 mg/kg/day	2 mg/kg/day	Decreased testosterone levels
	IVR	2 mg/kg/day	2 mg/kg/day	Affects steroidogenesis
	IVR	2 mg/kg/day	2 mg/kg/day	Affects steroid metabolism
	IVR	2 mg/kg/day	2 mg/kg/day	Decreased pregnenolone levels
	IVR	2 mg/kg/day	2 mg/kg/day	Decreased 17
	IVR	2 mg/kg/day	2 mg/kg/day
	IVR	2 mg/kg/day	2 mg/kg/day
	IVR	2 mg/kg/day	2 mg/kg/day
	IVTH	0.000000001 M	-
	IVTH	0.000001 M	0.000001 M
	IVTH	0.000001 M	0.000001 M
	IVTH	0.000001 M	0.000001 M
	IVTH	0.000001 M	0.000001 M
	IVTH	0.000001 M	0.000001 M
	IVTH	0.000001 M	0.000001 M
	IVTH	0.000001 M	0.000001 M
	IVR	8 mg/kg/day	8 mg/kg/day
	IVTH	0.000001 M	0.000001 M
	IVR	8 mg/kg/day	8 mg/kg/day
	IVTH	0.000001 M	0.000001 M
	IVR	8 mg/kg/day	8 mg/kg/day
	IVR	8 mg/kg/day	8 mg/kg/day
	IVR	8 mg/kg/day	8 mg/kg/day
	IVR	8 mg/kg/day	8 mg/kg/day
	IVR	8 mg/kg/day	8 mg/kg/day
	IVR	8 mg/kg/day	8 mg/kg/day
	IVR	8 mg/kg/day	8 mg/kg/day

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.